4th Quarter - Report

INOVIO PHARMACEUTICALS, INC. for INOVIO PHARMACEUTICALS, INC.

Firm
Client
Income
—
Expenses
$130,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Issues related to COVID-19 research and development, vaccine distribution and manufacturing; Next Generation COVID-19 vaccines and boosters; Issues related to ASPR/BARDA and manufacturing of COVID-10 vaccines and boosters; Issues related to Oncology and HPV cancers; Continuing Resolution (CR), H.R. 6833, the Continuing Resolution and Ukraine Supplemental Appropriations Act; FY2023 Omnibus Appropriations Act, H.R. 2617; Issues related to the Prescription Drug User Fee Act (PDUFA); Issues related to the Medical Device User Fees Amendment (MDUFA IV); ARPA-H Act, H.R 5585; Accelerated Approval Integrity Act of 2022, H.R. 6963; Prevent Pandemic Act, S. 3799; DNA Medicines awareness

LobbyistCovered position, as disclosed
COOKAB HASHEMI —

Contacted: HOUSE OF REPRESENTATIVES; SENATE; White House Office; Health & Human Services, Dept of (HHS)

Bills named: H.R. 6963 (117th), H.R. 5585 (117th), H.R. 6833 (117th), H.R. 2617 (117th), S. 3799 (117th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.